Alzheon Inc.

The First Oral Treatment For Alzheimers

About this Event

Alzheon, Inc. is a late-stage clinical-stage biopharmaceutical company revolutionizing the fight against Alzheimer’s disease.

Alzheon’s lead therapy, ALZ-801, is a first-in-class oral treatment targeting the root cause of Alzheimer’s. Their focus is on removing amyloid plaque in the brain. Their trials have shown ALZ-801 doesn’t have significant brain shrinkage or brain bleed issues that its competitors are facing. Alzheon Phase 2 data and initial Phase 3 data were so compelling that they decided to do a second Phase 3 to include more patients with the expectation of accelerated approval. This innovative solution has the potential to become a game-changer in a $1 trillion global market.

Key highlights:
  • Breakthrough Innovation: Focused on genetic risk factors and toxic amyloid oligomers, ALZ-801 is leading a new era of precision medicine for Alzheimer’s.
  • Scalable Market: With 6+ million patients in the U.S. alone, the demand for effective treatments is immense.
  • Proven Leadership: Alzheon’s executive team combines deep expertise in neurology and drug development with a track record of success.

Alzheon has a mission of investing in best-in-class, late-stage companies at fair value. They will advance innovation and create meaningful societal impact while realizing significant returns in the process.

Register to watch this Fireside Chat with Alzheon Director and vice chairman of the Board of the Goldman Sachs Foundation and GS Gives, Muneer A. Satter, to hear why the National Institutes On Aging awarded a $47M grant to fund the Phase 3 study of this drug.

Hosted by Steven Saltzstein, CEO, Force Family Office

Video On Demand

– Recorded

February 25

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.